TY  -  
T1  - Integrative genomic and drug sensitivity profiling of High-Risk Chronic Myeloid Leukemia Patients in the Context of Personalized Medicine 
SN  -  /  
UR  - URN:ISBN:978-951-51-7263-1; http://hdl.handle.net/10138/329546 
T3  -  
A1  - Awad, Shady 
A2  -  
PB  - Helsingin yliopisto 
Y1  - 2021 
LA  - en 
AB  - Chronic myeloid leukemia (CML) is an adulthood leukemia that accounts for 15% of all leukemia patients. The hallmark of the disease is the BCR-ABL1 fusion gene. The development of Tyrosine kinase inhibitors targeted therapy has led to dramatic improvement in CML management with the life expectancy of CML patients approaching normal rates. Nevertheless, certain challenges in CML management remain unmet. CML progression from the chronic phase (CP) to the blast phase (BP) occurs in 5% of CML patien... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - medicine 
N1  -   
PP  -  
ER  -